Phenex Pharmaceuticals AG is a drug discovery and development company, focused on small-molecule therapeutics.

We aim to utilize our unique team expertise and our proven drug discovery experience and platforms to develop innovative therapies for liver and gastrointestinal diseases as well as cancer.

Latest News

Position for cancer research scientist.PDF
Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I.

Recent Poster Presentations

Unexpected anti-diabetic effects and anti-fibrotic activities of LXR inverse agonists in mouse models of NADFLD/NASH.PDF
American Association for the Study of the Liver Diseases: “The Liver Meeting™ 2016”, November 9-13, 2018 San Francisco, USA
Identification and Profiling of PX-D26116, a potent Hydroxyamidine-based IDO1 Inhibitor.PDF
CIMT 2018 Annual Meeting, May 15-17, 2018, Mainz, Germany
A novel aryl hydrocarbon receptor antagonist (PX-A24590) with anti-tumor activity in a syngeneic mouse pancreatic cancer model.PDF
CIMT 2018 Annual Meeting, May 15-17, 2018, Mainz, Germany